Loading
A phase 1/2 trial of Pembrolizumab in colorectal cancer and endometrial cancer, run by Eikon Therapeutics, now recruiting.
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors is a phase 1/2 interventional study registered as NCT07262619 by Eikon Therapeutics, with 160 participants planned, started 2026-01-20 and due to reach its primary completion in 2029-03. Interventions recorded: EIK1005, pembrolizumab (KEYTRUDA® ). Conditions listed: Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Mismatch-repair-deficient endometrial cancer, Mismatch-repair deficient (MSI-high) colorectal cancer, Endometrial cancer, Colorectal cancer.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Eikon Therapeutics, Pembrolizumab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.